Albireo pharma inc says fda clears tco's new drug application to initiate trial in biliary atresia

Albireo pharma inc - u.s. fda cleared tco's investigational new drug (ind) application to initiate global pivotal trial in biliary atresia.albireo pharma - after scheduled fda interactions in q1 of 2020, co plans to commence additional pivotal program in alagille syndrome by end of 2020.albireo pharma inc - continues to expect topline data from phase 3 trial in pfic in mid-2020.albireo pharma - continues to anticipate current cash balance will be sufficient to meet operating needs into 2021.
ALBO Ratings Summary
ALBO Quant Ranking